



113

PTO SB 21 (08-00)  
Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	09/883,093	
	<b>Filing Date</b>	June 14, 2001	
	<b>First Named Inventor</b>	GUENTHER	
	<b>Group Art Unit</b>	1632	
	<b>Examiner Name</b>	Michael C. Wilson	
<b>Total Number of Pages in This Submission</b>	8	<b>Attorney Docket Number</b>	R-126

TECH CENTER 1600/2900

DEC 13 2002

RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/ <del>Reply</del> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input checked="" type="checkbox"/> Drawing(s) New Fig. 2A <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mariette A. Lapiz, Reg. No. 44,202
Signature	<i>Mariette A. Lapiz</i>
Date	December 4, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 12/4/02			
Typed or printed name	Deborah A. Mojarro		
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 13 2002

TECH CENTER 1600/2900

In re application of:

Catherine GUENTHER et al.

Application No.: 09/883,093

Filed: June 14, 2001

For: Transgenic Mice Containing Nuclear  
Hormone Receptor Gene Disruptions

Examiner: Michael C. Wilson

Art Unit: 1632

Atty. Docket No.: R-126

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to the examination of the above-referenced application and in response to the U.S. Patent Office Notice mailed November 14, 2002, entry of the following amendment is respectfully requested:

**In the Specification**

Please replace the paragraph on page 8, lines 12-15, with the following paragraph:

--Figure 2A-2B shows design of the targeting construct used to disrupt nuclear hormone receptor genes. Figure 2A, which illustrates the target sequence (SEQ ID NO:1) for the targeting construct, shows the location and extent of the disrupted portion of the nuclear hormone receptor gene, as well as the nucleotide sequences flanking the Neo<sup>r</sup> insert in the targeting construct. Figure 2B shows the sequences identified as SEQ ID NO:3 and SEQ ID NO:4, which were used as the targeting arms (homologous sequences) in the nuclear hormone receptor targeting construct.--

**In the Drawings**

Please replace Figure 2A in the application with the enclosed new Figure 2A. A marked-up copy of Figure 2A is also enclosed, with corrections indicated in red.

N/E